Switching from Biologic to Biosimilar: Australia’s Unique Approach
Switching patients from an originator biologic (the reference product) to a biosimilar version has been a topic of keen interest in recent years, both in Australia and globally, as...
Switching patients from an originator biologic (the reference product) to a biosimilar version has been a topic of keen...
Read More
Switching stances: China policies to focus strongly on patent quality
On March 5, the China National Intellectual Property Administration (CNIPA) issued key points for its goals in 2020, which were reiterated in a recent May newsletter. One of the...
On March 5, the China National Intellectual Property Administration (CNIPA) issued key points for its goals in 2020, which...
Read More
Pilkin v Sony Australia Limited
Mr Vitaly Pilkin appealed from a Federal Court decision summarily dismissing his patent infringement proceedings against Sony Australia and refusing leave to serve Sony entities out of jurisdiction in...
Mr Vitaly Pilkin appealed from a Federal Court decision summarily dismissing his patent infringement proceedings against Sony Australia and...
Read More
TGA transparency reforms (part 2): Early publication of major innovator prescription medicine applications
In Part 1 of this series (available here), we examined the impact of the proposal by Australia’s Therapeutic Goods Administration (TGA) to provide early confidential notification to innovators of applications under evaluation...
In Part 1 of this series (available here), we examined the impact of the proposal by Australia’s Therapeutic Goods Administration (TGA) to...
Read More
Singapore Patent Fast Track Programme
The Intellectual Property Office of Singapore (IPOS) has launched a new fast-track programme (named “SG Patent Fast Track”) to accelerate the patent application-to-grant process in Singapore. The programme is...
The Intellectual Property Office of Singapore (IPOS) has launched a new fast-track programme (named “SG Patent Fast Track”) to...
Read More
TGA transparency reforms (part 1): Notification of generic and biosimilar medicines to impact pharmaceutical patent disputes in Australia
Regulatory changes recently approved by the Australian Government are likely to impact the way in which pharmaceutical patent litigation is conducted in Australia. The Therapeutic Goods Administration (TGA) is...
Regulatory changes recently approved by the Australian Government are likely to impact the way in which pharmaceutical patent litigation...
Read More